During initial risk assessments, the metastatic potential of prostate cancer (PCa) may not be fully considered. The tumor’s multicentric origin, which is associated with genetic mutations, may explain existing treatment limitations.
During initial risk assessments, the metastatic potential of prostate cancer (PCa) may not be fully considered. The tumor’s multicentric origin, which is associated with genetic mutations, may explain existing treatment limitations.